Biosimilar Product Focus
The first biologic drug, humanized insulin, obtained market approval in 1982 and the first therapeutic monoclonal antibody in 1986. Today biopharmaceuticals make up between around 25% to 30% of new drug approvals in the US. There are currently over 70 approved antibody therapies on the market with several hundred in pre-clinical and clinical development. A huge number of biosimilar and interchangeable product versions of these drugs are being developed globally. This is a trend that will continue as more approved large molecule therapies come to the end of their patent life.
What are biosimilar drugs?
We offer a range of research use only biosimilar biological products to be used in basic research where the alternative is to purchase expensive and difficult to obtain therapeutic drugs. For example, when developing ligand binding or cell based bioanalytical assays or researching the biological effects of a drug in vivo, in vitro and ex vivo. Our research grade biosimilars are available in the original Human format or as a chimeric Rabbit antibody using the variable regions from the original Human version on a Rabbit backbone.
Original Human Version
Rabbit Chimeric Version
Research grade biosimilars are supplied in PBS and 0.02% proclin 300 so are free from excipients normally found in therapeutic versions.
Our range currently includes research grade versions of the following drugs:
Arcitumomab, Satumomab, Volociximab, Efalizumab, Rituximab, Clenoliximab, Ruplizumab, Campath-1H, Cetuximab, Matuzumab, Trastuzumab, Daclizumab, Basiliximab, Tocilizumab, Oxelumab, Infliximab, Humicade, Adalimumab and Bevacizumab.
Please remember that our research grade biosimilars are NOT for therapeutic use.